Abiopharma

🔍 Weiss Amir (Executive)

Company: TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Report Date: 2026-08-21

Detailed Transactions and Holdings:

• Sold 6,945 shares of Ordinary Shares at $37.6133 per share (Direct)
  Date: 2026-08-21 | Code: S | equity_swap_involved: false | shares_owned_after: 13,071.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 2,500 shares of Ordinary Shares at $19.61 per share (Direct)
  Date: 2026-08-21 | Code: M | equity_swap_involved: false | shares_owned_after: 15,571.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 2,500 shares of Ordinary Shares at $37.6307 per share (Direct)
  Date: 2026-08-21 | Code: S | equity_swap_involved: false | shares_owned_after: 13,071.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 2,500 shares of Stock Options (right to buy) at $19.16 per share (Derivative)
  Date: 2026-08-21 | Code: M | Expires: 2028-03-02 | equity_swap_involved: false | shares_owned_after: 7,502.00 | transaction_form_type: 4 | Footnotes: F3, F1

Footnotes:

• F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.61 to $31.62, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
• F3: Stock options were granted on March 3, 2018, with 2,500 having vested on each of March 2, 2019, March 2, 2020 and March 2, 2021 and 2,502 having vested on March 2, 2022.